ErbB2, a therapeutic target in cancer

Mark Lemmon group (University of Pennsylvania)


Using beamline 23ID-D and small-angle X-ray studies, Mark Lemmon's group of the University of Pennsylvania has gained new insight on the orphan receptor tyrosine kinase ErbB2, which is an important therapeutic target in human cancer. ErbB2 is unique among the four human ErbB receptors, including epidermal growth factor receptor (EGFR), in its ability to transform cells in absence of ligand when it is over-expressed. Ligand-induced activation of EGFR involves conformational changes in the extracellular region, where an exposed "dimerization arm" of domain II converts from a "tethered" state to an "extended" state. Previous structures of ErbB2 were in an "extended" state, consistent with a constituitively active "auto-activated" receptor that can form dimers independent of growth factor. The new structure shows that this model is unlikely to pertain to the ErbB2 sub-family. Drosophila melanogaster EGFR (dEGFR), although a close relative of ErbB2, is strongly regulated by ligands. Like ErbB2, dEGFR also is in an "extended" state. The new structure provides several mechanistic possibilities, all different from the hEGFR model.

Figure: (A) tethered, extended, and active states of human EGFR, with purple EGF, (B) human EGFR with bound EGF,
(C) ErbB2, (D) dEGFR.[ Figure reprinted by permission from Macmillan Publishers Ltd: Nature, copyright 2009]


Alvarado, D, Klein, DE, Lemmon, MA. ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor, Nature 461, 287-291 (2009). DOI: 10.1038/nature08297



GM/CA @ APS Sponsors: National Institute of General Medical Sciences (NIGMS) and National Cancer Institute (NCI) of the National Institutes of Health (NIH).

  GM/CA @ APS is an Office of Science User Facility operated for the U.S. Department of Energy by Argonne National Laboratory

  UChicago Argonne LLC | Privacy & Security Notice | Contact Us | A-Z Index | Search